EGFR and non-small cell lung carcinoma: In a Japanese study published by Minami et al. [28], it was reported that LIPI is a valuable prognostic factor only for specific subgroups of NSCLC patients treated with a tyrosine kinase inhibitor (EGFR, epidermal growth factor receptor).